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Abstract 
 
Background: Previous studies have shown significant anti-tumour effects of hyperbaric oxygen 
(HBO) treatment on chemically induced mammary tumours. Thus, to answer whether HBO has a 
general anti-tumour effect on mammary tumours, the study had three aims: 1. Establish two new 
mammary tumour models using eGFP (Green Fluorescent Protein) expressing immunodeficient mice 
and dsRed transfected tumour cells (4T1 and MCF7). 2. Elucidate possible effects of HBO treatment 
on tumour growth and angiogenesis. 3. Analyze the effect of HBO on the tumour interstitium.  
 
Methods: DsRed transfected cells were injected s.c. into the immunodeficient eGFP mice in the groin-
area. All mice received oestrogen treatment prior to injection. After tumour development (~3mm) the 
mice were divided into three groups. One group was exposed to repeated HBO treatments (3 
exposures), one to a single HBO treatment (both to 2.5 bar, 100% O2, à 90min) and controls to normal 
atmosphere (1 bar, 21% O2). Light microscopy, as well as multiphoton confocal microscopy, enabled 
investigation of the tumour-host interaction in situ. Treatment effects were determined by assessment 
of tumour growth (with calliper) and angiogenesis (CD31 staining). Moreover, tumour stromal factors 
such as Pif (with the wick-in-needle technique), collagen content (by hydroxyproline quantification) 
together with drug uptake ([3H]-5FU, using microdialysis) were measured. 
 
Results: Three million 4T1 dsRed cells injected in the eGFP mice induced tumours. The tumour cells 
invaded the stromal cells and a number of vascular elements were found in situ. Five million MCF7 
cells injected in conjunction with matrigel did also induce tumours, although this model has to be 
further elucidated. In the 4T1 mammary model, tumour growth and angiogenesis were significantly 
reduced after repeated HBO treatment compared to control. However, no change in collagen density 
was found. A significant reduction in Pif was found in both HBO treated groups. Nevertheless, this did 
not affect the drug uptake. 
 
Conclusion: We have successfully established a dsRed transfected 4T1 mammary tumour in eGFP 
expressing mice. We also developed MCF7 human mammary tumours, although this model needs 
further refinement. The reduction in 4T1 tumour growth found after HBO treatment can, to some 
extent, be explained by the reduction in angiogenesis. The collagen density was unchanged after HBO 
treatment, possibly due to the short treatment period. A reduction in Pif was found after HBO 
treatment, thus without inducing enhanced drug uptake. The mechanisms behind these effects need to 
be further elucidated.  
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“The scientist is not a person who gives the right 
answers, he's one who asks the right questions”.   
 
~Claude Lévi-Strauss, Le Cru et le cuit, 1964 
 
1 Introduction 
 
Tumour is the name of a swelling or lesion formed by an abnormal growth of cells. Tumour is 
not synonymous with cancer as a tumour is classified as being benign or malignant. In the latter 
case the tumour is a cancer. In this thesis we mostly use the term tumour when referring to 
cancer, as this is common in the literature.  
 
1.1 Cancer biology 
 
Cancer (medical term: malignant neoplasm) is a group of diseases characterized by 
uncontrolled cell growth, invasion and growth into adjacent tissue, as well as creating 
secondary tumours in other parts of the body (metastasis). The different types of cancers are 
characterised based on their tissue of origin. Cancer occurring in epithelial cells are classified 
as carcinomas, cancers from mesodermal cells are called sarcomas and cancers of glandular 
tissues are called adenocarcinomas [1].  
 
The different types of cancer differ widely in their causes and biology. However, Hanahan and 
Weinberg [2] have defined six characteristic hallmarks of most cancers: 
 
1. Growth signal autonomy: 
Cancer cells do not depend on external growth factors for their cell growth. 
2. Invasion of growth inhibitory signals: 
 Cancer cells do not respond to growth inhibitory signals. 
3. Evasion of apoptosis: 
Cancer cells evade apoptotic signals, and this contributes to maintain mutations. 
4. Unlimited replicative potential: 
Cancer cells can regulate telomere length, which result in unlimited replicative potential 
for the cancer cells. 
 
                                                                                                                 Introduction  
 2  
5. Angiogenesis: 
Cancer cells induce growth of new vessels in order for them to survive and expand. 
6. Invasion and metastasis: 
The cancer cells have the ability to move to other parts of the body and create secondary 
tumours. Metastasis is the major cause of cancer deaths.  
 
These hallmarks allow the cancer cells to grow and invade healthy tissue. In addition to these 
six common tumour properties, there are also three other very important properties, and these 
will be the focus of this thesis:  
 
• hypoxia (a factor that influences all the above hallmarks) [3] 
• interstitial hypertension [4] 
• fibrosis [5] 
 
1.2  Breast Cancer 
 
Breast cancer is a malignant, metastasizing cancer of the mammary gland, and classifies, 
therefore, as an adenocarcinoma. The female breast is made up of lobules, ducts and stroma. 
Most breast cancers origin from the cells that line the ducts, some from the cells that line the 
lobules, while a small number origin from other tissues of the breast [6].  
 
Breast cancer is the most frequent neoplasm in Norwegian women with 2761 new reported 
cases in 2007. According to calculations done by the Norwegian cancer registry 1 of 12 
Norwegian women will develop breast cancer before reaching the age of 75 [7]. In 2006, 679 
persons died from breast cancer in Norway [7], in spite of receiving treatment forms such as 
surgery, drugs (hormones and chemotherapy) and radiation. 
 
1.3  An immunodeficient mouse model 
 
It is important to better understand how the cancer cells progress and how they communicate 
with their microenvironment in order to find more effective and specific treatment options in 
the future [8]. It is well established that the behaviour of cancer cells are strongly influenced by 
their healthy surrounding environment [4]. Traditionally, cancer treatment has focused on 
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targeting the tumour cells directly. More recent research shows that tumour cells interact with 
and are dependent on surrounding normal cell types in the tumour [8, 9]. Targeting non-
malignant cell types, in addition to targeting tumour cells show promising results in 
combination with the traditional use of chemotherapeutic agents [5, 10-12].  
 
We used non-obese diabetic/severe combined immunodeficient (NOD/Scid) mice expressing 
enhanced-Green Fluorescent Protein (eGFP) in this study. The NOD/Scid mice are genetically 
modified to express eGFP in all nucleated cells, except for the blood-cells [13]. GFP is 
originally a protein found in the jelly fish Aequorea Victoria, and it absorbs blue light and 
emits green fluorescence when exposed to UV light. The eGFP is an artificial variant of GFP. 
The presence of GFP can be monitored in eGFP expressing NOD/Scid mice when they are 
exposed to appropriate UV illumination [14]. To be able to potentiate the benefits of the eGFP 
mouse-model a tumour is needed that can easily be differentiated from the green cells in the 
mice. This is commonly done by transfecting the tumour cells with a contrasting fluorescent to 
the green fluorescent expressed by the mice in vivo. We have chosen the red fluorescent 
protein, dsRed, as previous research with this combination have demonstrated good results 
[13]. Thus, the tumour-host interaction can be studied both in situ and ex vivo. Moreover, by 
using fluorescence-activated cell sorting (FACS) we will be able to completely separate the 
host cells from tumour cells. This provides a system for detailed cellular and molecular 
analysis of tumour-stroma interactions both on gene and protein levels (see Further Studies). 
 
1.4  The normal interstitium 
 
The interstitium is defined as the extracellular fluid compartment outside the cells, vascular and 
lymphatic system [15], and it provides mechanical and structural support within and between 
different tissues. It plays a central role in the control of cell proliferation, differentiation and 
migration, mediating cell adhesion and cell communication [15]. Further, it is the space where 
water and it’s dissolved constituents, moves from the blood plasma to the lymphatics. All 
organs have an interstitium and even though the constituents and architecture are the same, the 
relative amounts may differ from organ to organ [15]. 
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The interstitium contains two major components (Fig. 1):  
 
1. Structural components: 
• Collagen fibre bundles 
• Glycosaminoglycans (GAGs) 
• Cells (e.g. fibroblasts) 
 
2. Fluid compartment 
 
 
 
 
 
Figure 1: Schematic drawing of the constituents of the normal interstitium and the transcapillary-
interstitial fluid exchange system. With permission [16]. 
 
 
1.4.1 Structural components 
 
Collagen is synthesized by fibroblasts. They are a group of proteins with molecules consisting 
of three separate left-handed coiled polypeptide chains, each containing about 1000 amino 
acids [15]. Each of these coils are again coiled into a superhelix structure. The collagen 
molecules are organized in fibrils and subsequently they form fibres. The collagen fibre 
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bundles allow a certain flexibility, but are resistant to elongation and are, therefore, important 
in stabilizing normal tissue fluid volume by opposing tissue expansion [17].  
 
Glycosaminoglycans (GAGs) 
The GAGs are long polymers of aminosugars. They are synthesized and extruded through the 
plasma membrane of fibroblasts. They function as:   
• water-attracting expansion elements 
• determinants of the hydraulic conductivity of the interstitium [18]. 
 
The GAGs can be grouped into hyaluronan (HYA) and proteoglycans. When covalently bound 
to a protein backbone, they are called proteoglycans. These molecules are immobilised in the 
interstitium while HYA has never shown to be immobilized. HYA differs from the 
proteoglycans by not making a bond with the proteins, and this is the reason they are not bound 
in the interstitium. [15].  
 
Multiple proteoglycans are anchored to each HYA chain [18]. The HYA molecules attract 
water to cause tissue swelling and are an important constituent of the extracellular matrix [5]. 
The interstitial fluid is trapped mainly in the minute spaces among the proteoglycan filaments. 
This combination gives the interstitial fluid a gel-like substance making it difficult for fluid to 
flow easily through the interstitial tissue [17]. 
 
Cells 
The fibroblasts are the main cell type in connective tissue, and demonstrate both morphological 
and functional features closely related to the extracellular matrix (ECM). The fibroblasts are as 
mentioned earlier, responsible for synthesis of several components of the ECM, including 
collagen and HYA. The fibroblasts are able to exert tension on the collagen microfibrillar 
network through collagen binding integrins (Fig. 1 and 4). This collagen network restrains the 
intrinsic swelling pressure of HYA and proteoglycans in the matrix [19]. 
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1.4.2 Fluid compartment 
 
In an average adult male weighing 70 kg about 60% of the total body weight is water. This 
adds up to 42 litres of fluid with 28 of these litres found inside the cells, while 14 litres are 
found outside the cells and are referred to as interstitial fluid [20]. The interstitial fluid serves 
as a transport medium for nutrients and waste products between cells and capillary blood. It 
contains almost the same constituents as plasma except for 40-50% lower protein 
concentration, because the proteins cannot pass out of the capillaries with ease [21]. The 
transport of fluid and solute molecules in the interstitium is governed by the biological and 
physiochemical properties of the interstitium as well as the physiochemical properties of the 
molecule [22]. Transport of materials across the vessel wall is mainly governed by diffusion, 
and the factors influencing diffusion over the capillary wall are summarized in Fick’s law [18]. 
 
Equation 1: Fick’s law 
 
( )xCDAJ S ∆∆−= /  
 
Js=  The mass of solute transferred by diffusion per unit time  
∆C=  The concentration difference across the capillary wall  
∆x=  Distance (thickness of the capillary wall)  
A=  Surface area 
D=  The diffusion coefficient (inversely related to solute size) 
 
 
1.5  The Starling forces in normal tissue (transendothelial transport) 
 
The fluid volumes are being kept fairly constant by several buffering mechanisms including 
adjustment of forces across the capillary wall [4, 15]. The forces that determine the 
transcapillary fluid balance are the properties of the capillary membrane and the transmural 
hydrostatic and colloid osmotic pressures across the capillary. Ernest H. Starling described this 
relationship in 1896 [23], and the transcapillary fluid flux is often described according to 
Starling’s hypothesis as presented in Equation 2:  
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Equation 2: The Starling equation. 
 
Jv= LpS [ (Pc-Pif )- σ (COPc-COPif) ] =LpS x ∆P 
 
Jv = transcapillary fluid flux 
Lp = hydraulic conductance 
S = surface area of the capillary wall 
σ = reflection coefficient 
Pc = capillary hydrostatic pressure  
Pif = hydrostatic pressure of the interstitium 
COPc = colloid osmotic pressure of the capillary 
COPif = colloid osmotic pressure of the interstital fluid 
∆P = the net capillary filtration pressure 
 
The filtration is highly dependent on the product of the hydraulic conductance (Lp) as well as 
the surface area of the capillary wall (S). The reflection coefficient (σ) describes the 
permeability of proteins across the vessel wall, with σ=1 for impermeable vessels and σ=0 
when the membrane is freely permeable for proteins [15].  
 
Colloid osmotic pressure is built up by the tendency of water to diffuse through the semi-
permeable vessel wall, into the fluid compartment with the higher concentration of proteins [5]. 
The quantity of proteins found in the fluid compartment determines the colloid osmotic 
pressure in the interstitium. As mentioned earlier the proteins do not cross the capillary wall 
with ease. This results in a higher colloid osmotic pressure in the capillary (COPc) than in the 
interstitium (COPif), thus maintaining normal fluid levels within the capillaries (Fig. 3).  
 
Hydrostatic pressure is the pressure exerted by the blood, or the interstitial fluid on the 
capillary wall. The primary force for driving filtration is capillary blood pressure (Pc). The 
filtration is, however, opposed by the COPc [5]. 
 
The interstitial fluid pressure (Pif) is the pressure exerted by the interstitium, and normally 
varies between 0 and -2 mmHg in skin [15]. Pif is crucial in controlling a stable fluid volume in 
the interstitium and is mainly determined by the capillary fluid filtration and the lymph flow. In 
addition, the forces governed by the structural network of the interstitium are, probably, a 
contributing factor in the regulation of Pif.  
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Net capillary filtration pressure (∆P) is the pressure created from the imbalance between 
hydrostatic and osmotic pressure, normally resulting in filtration of fluid from the capillaries 
into the interstitium. This filtration adds up to approximately 3 litres per 24 hours in a grown 
adult weighing 70 kg. The filtered fluid will be transported away from the interstitium with the 
lymphatic system, along with any filtered plasma proteins that have escaped from the 
circulating blood to become part of the interstitial fluid, and be returned to the blood circulation 
again [17]. 
 
1.6  The tumour interstitium and surrounding microenvironment 
 
Although the normal interstitium and the tumour interstitium consist of the same components, 
there are some major structural and organizational differences (Fig. 2). The tumour interstitial 
compartment is characterized by a large interstitial fluid volume, high collagen concentration, 
low proteoyglycan and hyaluronan concentrations and absence of an anatomically well-defined 
functional lymphatic network [22]. Furthermore, tumours contain an increased number of 
fibroblasts, which bind to the collagen fibres in an integrin-dependent manner and thus exerting 
increased tension between the fibres [24]. They also contain an increased number of 
macrophages and other inflammatory cells that release cytokines and growth factors that act on 
cells of blood vessels and stromal fibroblasts [5]. To summarize, the tumour interstitium is 
denser and more rigid than normal loose connective tissue. 
 
Figure 2: Structural differences between normal (upper panel) and tumour tissue (lower panel). With 
permission [5]. 
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Normal and healthy vasculature is well organized and evenly distributed as well as being 
selectively permeable and surrounded by supporting pericytes. In comparison, the vasculature 
in malignant tumours is formed by angiogenesis, making them disorganized and chaotic, with 
varying diameters of the lumen and frequent bifurcations (Fig. 2) [4]. The vessels have loops 
and shunts resulting in long transit times and path lengths. In addition they lack pericytes that 
support the vessel walls [4, 10]. These features make the vasculature very permeable to water 
and small proteins, resulting in a loss of both proteins and water into the interstitial space, thus 
leading to a disturbance in the Starling balance. 
 
1.7  The Starling forces in tumour tissue. 
 
Interstitial hypertension (↑Pif) is a major difference in the Starling forces when comparing 
tumour tissue to normal tissue (Fig. 3). The Pif in tumours, typically range between 10-30 
mmHg, compared to the normal interstitial fluid pressure of ∼ -1mm Hg (Fig. 3). Pif is evenly 
elevated throughout much of the central tumour region and falls to near zero at the periphery 
[25, 26]. 
 
 
Figure 3: The Starling forces in normal tissue and tumour tissue. With permission [5].  
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The mechanisms behind the increased Pif in tumours, is not yet fully understood. However, it is 
believed that elevated pressure in solid tumours is caused by: 
 
1. High vascular permeability.  
Due to leaky tumour vessels, fluid accumulates in the interstitium, causing Pif to 
rise [5].  
 
2. Irregular vascular architecture.  
Irregular vascular architecture as well as vascular compression caused by 
proliferating cancer cells, contributes to high intravascular pressure, which is 
reflected in the interstitial pressure [27].  
 
3. Non-functional tumour lymphatics. 
The lymphatic vessels in the tumour are often malformed and compressed and, 
therefore, unable to drain free interstitial fluid back into the central venous 
circulation. This causes a further increase in Pif [4].  
 
4. High collagen content.  
It seems that volume changes in tumour tissue are more restricted than in normal 
tissue, probably because of the denser connective tissue molecules that characterize 
tumour stroma. The formation or development of excess fibrous connective 
(collagen) tissue will increase the tumour Pif. This is likely to contribute to the 
persistence of the increased Pif in some tumours [5]. 
 
5. Increased contractility of fibroblasts 
Fibroblasts play a pivotal role in the development of high Pif values. The fibroblasts 
are able to exert tension on the collagen microfibrillar network through collagen 
binding integrins (Fig. 1 and 4), thus making the tumour environment more rigid 
[19].  
 
 
                                                                                                                 Introduction  
 11  
 
Figure 4: A proposed mechanism for dynamic control of interstitial fluid pressure. Modified from Reed 
[24]. 
 
It is well established that an increased Pif interferes with the uptake of chemotherapeutic agents 
[5, 28]. Drugs move from the vasculature into the interstitium and then through the interstitium 
either by diffusion along a concentration gradient or by convection along a hydrostatic pressure 
gradient [4, 11].  
 
To make the systemic distribution of a chemotheraputic agent efficient, there are two main 
demands:  
1. The drug must reach the target cells by crossing the capillaries, and 
diffuse through the interstitial matrix.  
 
2. The drug must be effective in the tumour microenvironment. 
 
Multiple strategies to reduce Pif are associated with increased drug levels in tumours and 
greater chemotherapy effectiveness [4, 28-31]. The potentiated effect of the Pif reducing 
treatment has been observed on both tumour growth retardation as well as changes in tumour 
morphology [28]. In addition, interstitial transport is determined by the structure and 
composition of the interstitial compartment. Therefore, the ECM itself may contribute to the 
drug resistance of a solid tumour, by preventing the penetration of macromolecules like 
chemotherapeutic agents into the tumour cells. Thus, showing that altered and denser collagen 
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organization, characteristic for the tumour interstitium, influence the tissue resistance to 
macromolecule transport. This is possibly due to the binding and stabilizing of the GAG 
component of the ECM [32]. 
 
If the chemotheraputic agents have managed to cross the capillaries and reach the cancer cells, 
different properties of the tumour microenvironment will affect the efficiency and uptake of the 
drug. One of these factors is tumour hypoxia, a trait that is well established in all types of solid 
tumours [33-35].  
 
1.8  Tumour hypoxia  
 
A cell cannot survive without being provided with nutrients and having waste products 
removed by a functional vessel system in close proximity. Tumours do not exhibit a 
homogenous and functional vascular network, thus, central parts of the tumours develop 
hypoxia [26]. While normal, healthy tissue can compensate for oxygen deficiencies by 
increasing blood flow to the deprived area, large tumours are not able to compensate for the 
lack of oxygen, and develop hypoxia. Thus, the primary determinant that governs the 
progression of the tumour is its proximity to a vascular supply.  
 
The new tumour blood vessels develop from pre-existing vasculature, by angiogenesis. The 
induction of angiogenesis is a consequence of an imbalance between multiple inhibitor and 
stimulator molecules, referred to as the “angiogenic switch” [36]. One of the precursors of 
angiogenesis is the hypoxic trait of tumours. Proteins activate angiogenic programs in 
endothelial cells that signal a number of biological responses, including directional migration, 
invasion, cell division, proteolysis, expression of anti-apoptopic proteins, and ultimately, new 
capillary formation [8, 37, 38]. It is somehow paradoxical that the tumour tissue is hypoxic due 
to abnormal and non-functional tumour vasculature, as the hypoxic tumour tissue was 
responsible for inducing angiogenesis in the first place [39]. 
 
There are different types of hypoxia in tumours; chronic and acute. The original concept of 
hypoxia in tumours was proposed by Thomlinson and Gray in 1955, and refers to diffusion-
related hypoxia [39, 40]. Diffusion-related hypoxia (chronic) is a consequence of tumour cells 
that are distant from the vascular supply, and result in an inadequate O2 supply for cells far 
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away from the nutritive blood vessels. In order to grow a solid tumour, the tumour is dependent 
on angiogenesis to be able to expand [10].  Later the concept of perfusion-limited hypoxia 
(acute) emerged [41], meaning that too little oxygen was delivered to the tumour. The 
microvasculature in tumours has severe structural and functional abnormalities as well as being 
surrounded by a high density of tumour cells compressing the blood vessel. These two factors 
cause inadequate blood flow in the tissue. Studies of blood flow and oxygen levels in animal 
tumours have established that perfusion of blood vessels can change dynamically in time, 
leading to rapid but transient episodes of severe hypoxia in the tumour cells [39].  
 
Since tumour oxygenation can fluctuate over time, tumour cells most likely shift between 
levels of hypoxia and more oxygenated states. In conclusion, regions of both acute and chronic 
states for hypoxia contribute to the overall level of hypoxia in different tumours.  
 
Over the last decade it has become clear that tumour hypoxia plays an important part in tumour 
progression, growth and invasion and in the development of a more aggressive phenotype [3, 
35, 39, 42]. Our hypothesis is therefore that a reduction in the hypoxic state of the tumour 
might have an inhibitory effect on tumour growth per se in addition to enhancing the uptake 
of chemotherapy. Thus, one way of enhancing the pO2 in the tumour tissue is the use of 
hyperbaric oxygen treatment. 
 
1.9  Hyperbaric oxygen treatment (HBO) 
 
HBO therapy is defined as the administration of 100% inhaled oxygen at increased atmospheric 
pressure [43]. At normal atmospheric pressure (1 bar = 760 mmHg), haemoglobin is around 
97% saturated with oxygen. Thus, a further increase in oxygen pressure or concentration has 
little or no impact on the total haemoglobin oxygen concentration. Approximately 0.31 ml of 
oxygen is dissolved in plasma as can be seen from Table 1. However, the ability to enhance the 
transport of physiologically dissolved oxygen can be markedly elevated by HBO as indicated 
in Table 1. When oxygen is dissolved in plasma, it can more easily reach tissue areas where 
oxygen supply is diffusion limited. Further, dissolved oxygen can enable tissue oxygenation 
despite impaired haemoglobin carriage capacity. Thus, HBO treatments can cause up to a four-
fold increase in the distance that oxygen can diffuse in tissue, by elevating the partial oxygenic 
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pressure (pO2) in arterial blood. According to Henry’s law (gas law): “a gas is dissolved by a 
liquid in direct proportion to its partial pressure”, as illustrated in Table 1. 
 
Table 1: Theoretical arterial oxygen tension and oxygen blood content when exposed to different 
oxygen (%) levels under varying pressure values (bar). 
 
 
Oxygen % level Bar Arterial oxygen tension (mmHg) ml of oxygen physically 
dissolved in plasma  
21 1 100 0.31 
100 1 760 2.0 
100 2 1400 4.3 
100 3 2200 6.8 
 
 
The Undersea and Hyperbaric Medical Society (UHMS) has a list of 13 approved indications 
for hyperbaric oxygen therapy (Appendix A). Thus, HBO as a treatment, has been shown to be 
used safely, without side effects, in humans up to 2.8 bar (18msw), for 90 min each time and 
over a period of several days (continuous) [44]. 
 
1.10  HBO and cancer  
 
In the 1960’s there were several studies evaluating HBO as a tumour promoter, in order to 
elucidate whether the accepted HBO therapies (UHMS) was contradictory when treating 
patients with malignant tumours. Nevertheless, in a review by Feldmeier et al [45] they 
conclude that HBO does not potentiate tumour growth. Surprisingly, recent studies at our 
laboratory have concluded that HBO has a significant inhibitory effect on the growth of DMBA 
(chemically) induced mammary tumours per se [46-48] as well as gliomas [49]. These studies 
have, contrary to earlier studies, gone beyond the simple study on the growth of tumours and 
the number of metastasis, and gone into more detail concerning changes in morphology, 
histology, physiology and in gene expression. Furthermore, others have shown that mouse 
MT7 mammary carcinoma xenografts had reduced numbers of metastatic lung colonies after 3 
weeks of exposure to 70% O2 [50, 51]. A study on oral mucosal carcinomas in Syrian Hamsters 
and one on S-180 sarcomas in mice have also shown that HBO attenuated tumour growth [52, 
53]. 
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The main background for the present study is the work by Stuhr et al. [47] Raa et al. [46] as 
well as Moen et al [48], on DMBA induced mammary tumours. They showed that increasing 
the oxygen content in the mammary tumour, by normobaric and hyperbaric hyperoxic 
treatment, induced significant changes in tumour physiology, anatomy and gene expression as, 
shown in Fig 4. 
A DMBA-induced
mammary tumour
pO2
Tumour growth* 
Anti-angiogenesis*
Apoptosis*
Proliferation* Less agressive*
(Shift of a whole gene program)
Histological changes
Anti-fibrotic effect *
(reduced collagen content)
Metabolic change*
(from glycolytic to aerobic)
* Gene expression changes corresponded to the histological findings
Interstitial fluid pressure
Drug uptake
 
Figure 5: Schematic drawing of the effects of hyperoxia found on DMBA-induced mammary tumours 
in rats. 
 
 
The study by Stuhr et al. 2004 also showed that 7 HBO exposures over a period of 23 days, 
kept the tumour size considerably below day 1 levels and that the effect reached a maximum 
after 4 exposures [47]. Tumour growth was also found to be suppressed for at least 12 days 
after HBO completion [47]. This implies that HBO exposure actually reduces the tumour to a 
certain size and thereafter prevents it from growing further.  
 
On this background, we wanted to add two new mammary tumour models (one murine and 
one human) to verify if HBO has a general anti-tumour effect on mammary tumours. 
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1.11  Aims of the study 
 
 The three aims of this study were to: 
 
1. Establish two new mammary models by using eGFP expressing immunodeficient mice and 
dsRed transfected tumour cells. 
 
2. Elucidate the possible effect of HBO treatment on tumour growth and angiogenesis. 
 
3. Analyse the effect of HBO treatment on the tumour interstitium (Pif and collagen content) as 
well as the effect of drug uptake (chemotherapeutic effect).  
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2 Materials and methods 
 
2.1  Cell lines and culture conditions 
 
The present study includes two different dsRed transfected adenocarcinoma cell lines; the 
murine mammary cell-line (4T1) and the human mammary cell-line (MCF7). Both cell-lines 
were obtained from the American Type Culture Collection (Rockville, MD, USA). The cell-
lines were pre-transfected with the red fluorescence, dsRed. 
 
The murine mammary cell-line, 4T1, was originally isolated from a spontaneously arising 
mammary tumour in BALB/cfC3H mice [54]. The 4T1 mouse mammary tumour cell line is 
one of a few breast cancer models with the ability to metastasize to sites affected in human 
breast cancer, making it a good model of human metastatic breast cancer [55]. It metastasizes 
via the haematogenous route to liver, lungs, bone and brain, [54].  
 
The MCF7 cell-line originates from a 69 year old Caucasian female, and was derived from a 
pleural perfusion procedure. The MCF7 cell line is capable of forming tumours in 
immunodeficient mice and the growth has been shown to be strongly oestrogen dependent 
[56]. 
 
All cell culture work was performed in a sterile environment using a laminar flow bench with 
a HEPA filter (Thermo Scientific, USA). The cells were cultured in standard plastic tissue 
culture flasks 75 cm2 (NUNC, Roskilde, Denmark) with RPMI-1640 medium (Bio-Whittaker, 
Verviers, Belgium) supplemented with 10% Foetal Calf Serum (Sigma-Aldrich, Steinheim, 
Germany), 100 units/ml penicillin, 100 µg/ml streptomycin, 2% L-glutamine (all from Bio-
Whittaker). The cells were amplified as a monolayer at 37ºc in a humidified incubator with 
5% CO2 and 95% air and were seeded until about 80% confluence.  
 
When not in need of the cells, they were frozen and placed in a liquid nitrogen container and 
thawed when needed again (Appendix B). This procedure reduced the number of passages.  
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When observed through a microscope (AxioImager 2, Carl Zeiss MicroImaging, GmbH, Jena, 
Germany) we confirmed that both the 4T1 cells and the MCF7 cells in culture were 
successfully transfected with dsRed, as they displayed red fluorescence (Fig. 6).  
 
Figure 6: Fluorescence microscopy pictures of the 4T1 cells (left) and MCF-7 cells (right). 
Magnification (x4). Scalebar indicates 50µm. 
 
2.2  Animals 
 
A total of 60 female NOD/Scid mice with a minimum weight of 18 g were used in this study. 
37 of the 60 NOD/Scid mice expressed eGFP in all nucleated cells. The eGFP protein absorbs 
blue light and emits green fluorescence without exogenous substrates or cofactors (Fig. 7).  
 
 
 
Figure 7: Mice expressing enhanced green fluorescent protein (eGFP) under UV illumination (with 
courtesy from Lene Nybø). 
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The transgenic mice were produced by using the GFP coding sequence ligated with the 
chicken beta-actin promoter, and were bred at the University of Bergen by crossing 
NOD.CB17.Prkdcscid mice (stock no. 003291) with C57BL/6-Tg (ActB eGFP) mice (stock no. 
001303) (Jackson Laboratory, Bar Harbour, ME, USA). Further, the breeding was performed 
between heterozygous eGFP and homozygous NOD.CB178.Prkdcscid genotyped by 
polymerase chain reaction (PCR) analysis, and organized by the technical staff at the animal 
facility at the Department of Biomedicine [13]. The green fluorescence from the eGFP was 
later observed in muscle, pancreas, kidney, heart and other organs of the mice, confirming 
that the procedures were successful [57, 58]. 
 
We did not use eGFP expressing mice when measuring Pif and performing microdialysis, as 
we did not need to separate the tumour tissue from the host cells. Furthermore, the eGFP mice 
are difficult to breed and expensive. Instead we used plain NOD/Scid mice. 
 
The mice were housed in individually ventilated cages (Makrolon IV, Techniplast Gazzada 
S.a.r.l., Buggugiate, Italia). They had access to food (Rat and mouse nr.1, Special Diet 
Service, Witham Essex, UK) and water ad libitum, and the temperature in the animal facility 
was kept at a constant temperature of 21ºC, the air humidity between 40-60%, and the 
light/dark cycle was 12/12 hours. The mice were identified by labelling the base of their tales 
using a permanent marker.  
 
All the experiments in this Master Thesis were performed in accordance to the Norwegian 
Committee for Animal Research. The number of animals was minimized to comply with the 
guidelines from the Ethical Committee. So whenever possible, we injected the mice with cells 
in each side of the groin to obtain two tumours for each mouse. This was done when 
measuring the interstitial pressure, as well as when collecting tumour tissue and measuring 
growth.  
 
2.3 Anaesthesia  
 
All the animal procedures were performed under a short Isoflurane (Rhone-Puolenc 
Chemicals, France) and N2O gas-anaesthesia. The only exception being the microdialysis 
protocol, which was performed with a subcutaneous injection of Midazolam (Dormicum, F. 
                                                                                                                  Materials and methods 
 22  
Hoffmann-La Roche AG, Basel, Sveits) in combination with Fentanyl/Fluanison (Hypnorm, 
Janssen Pharmaceutical, Beerse, Belgium) (Hypnorm-Dormicum) due to the substantial 
duration and need for immobilization of the animal during the procedure.  
 
During gas-anaesthesia the mice were placed in a plexiglas anaesthetic chamber, flushed with 
O2 (1.0 l/min), together with compressed air (1.0 l/min). Isoflurane was added at a dose of 3 
l/min.  When the mouse was satisfactorily anaesthetized, we reduced the dose of Isoflurane to 
1.5-2.0 l/min and continued the anaesthesia supply by a nozzle to the nose/mouth area.  
 
When administering Hypnorm-Dormicum, both anaesthetic agents were mixed individually 
with NaCl (1:1), before being mixed together (1:1) and administered to the mouse 
subcutaneously. The Hypnorm-Dormicum was administered at a dose of 30mg/kg, with an 
initial volume of ∼0.2 ml, and with an addition of ∼0.1 ml after one hour.  
 
We tested the contraction reflex as a sign of sufficient anaesthesia by pinching the sole of the 
back foot with a set of tweezers.  
 
An artificial heating source was utilized during surgical and experimental procedures, keeping 
the mouse rectal temperature at approximately 37°C at all times. 
 
2.4  Establishing tumours  
 
To be able to identify the number of cells/ml solution, the cells were trypsinized into a single 
cell suspension. The cells were then counted by using the cell nucleocounter (Bergman-
Nucleocounter-chemometech, Allerød, Denmark). In accordance with the manufacturer’s 
instructions, 200 µl of both buffer A and B (Bergman-Nucleocounter-chemometech, Allerød, 
Denmark) was added to 200 µl of the single cell suspension. The lysis Reagent A has a pH of 
about 1.25 and is added to disrupt the plasma membranes of the cells, leaving the nuclei 
susceptible to staining with the fluorescent dye propidium iodide (PI) (at a later step in the 
process). The Reagent A also contributes to disaggregate cell clusters. The stabilizing Reagent 
B was added following Reagent A, in order to raise the pH value, as the increased pH enables 
the PI to stain the DNA of the cells more efficiently. The solution was then centrifuged 
(LABINCO L46, Breda, Netherland) before being loaded into the nuclecassette. The 
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nucleocassette (Bergman-Nucleocounter-chemometech, Allerød, Denmark) is a disposable 
cassette filled with PI. The cassette automatically loads 50 µl of the cell solution. Here it is 
dissolved and mixed with the PI. This step stains the nuclei of the cell, and makes it possible 
for the cell nucleocounter to count the number of cells pr ml. The amount of cells/ml has to be 
multiplied by three due to the dilution caused by the added buffers.  
 
Before injecting the cells they were centrifuged (Heraeus instruments, Megafuge 1,0 R, 
Hanau, Germany) and the RPMI-1640 medium was replaced with Phosphate Buffered Saline 
(PBS) (Sigma-Aldrich-Company, Steinheim, Germany).  
 
We initially injected 2 mice (for each cell-line) with approximately 2x106 cells in 0.2 ml PBS. 
This was performed as a pilot study to see if we could obtain tumours. If so the tumours 
would be frozen and used as a stock for later use. 
 
All the mice were given 17β-estradiol in the form of a pellet (0.18 mg/pellet- 60 day release, 
Innovative Research of America, Sarasota, FL, USA). The pellet was inserted under the skin 
in the interscapular area so as to stimulate tumour growth. The pellets provided a continuous 
release of estradiol at serum concentrations of 150-250 pM. 
 
4T1 
The injected 4T1 cell line developed tumours in the mice in approximately 10 days. The 
tumours were quickly dissected out, placed in a Petri Dish and cut into small pieces of 
approximately 2 × 2 mm. The tissue samples were then placed in a special freezer medium 
(Appendix C) in small eppendorf tubes, and placed in a box filled with isopropanol (Arcus 
kjemi AS, Pnr 2204, Vestby, Norway). The isopropanol box was left in the -80ºC freezer for 
16-24 hours. The samples were then transferred to a container filled with liquid nitrogen and 
subsequently put in the -85ºc freezer, marked and ready for later use.  
 
From the frozen stock of 4T1 tumours, minced tumour pieces mixed with PBS was injected in 
the fat pad. Each mouse received approximately 1 tumour piece (~2×2 mm). After monitoring 
the mice over a period of 8 weeks, we concluded that the attempt was unsuccessful, as no 
tumour was detectable. Thus, we decided to continue by inserting the cell lines directly, as 
done initially. The number of 4T1 cells injected was increased from 2x106 cells to 3x106 cells 
in an attempt to speed up the latency period (the time it took for the tumour to develop). 
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MCF7 
As the MCF7 cell line did not develop tumours when injecting 2x106 cells (followed for 8 
weeks) we increased the amount of MCF7 cells to 5x106, a quantity supported in literature 
[59]. However, this still did not result in tumours. Therefore, we attempted to suspend the 
cells in 0.2 ml BD Matrigel (BD MatrigelTM Basement Membrane Matrix High 
Concentration, Phenol Red Free, BD Bioscences, Bedford, USA) before injecting them into 
the fat-pad of the mouse. BD Matrigel Matrix (matrigel) has previously shown to be effective 
for the attachment and differentiation of the human tumour cells in the mouse tissue [56]. 
 
All the mice were checked for tumour growth three times per week by palpating the area of 
injection. Once the tumours reached a diameter of ~ 3 mm, mice were randomized into three 
groups as described in chapter 2.5. 
 
2.5 Experimental groups  
 
Three separate groups of mice were studied as illustrated in Table 2. 
 
Table 2: An overview of the different experimental groups. 
 
 
Experimental 
groups Gas 
Ambient 
pressure 
 
 
pO2 
 
Number of 
exposures 
 
Exposure 
time 
 
Control 
 
air 
 
1 bar 
 
0,2 
 
- 
 
- 
 
Repeated HBO 
treatment 
 
O2 
 
2.5 bar 
 
2.5 
 
3* 
 
90 min 
 
Single HBO 
treatment 
 
O2 
 
2.5 bar 
 
2.5 
 
1** 
 
90 min 
   
 
        * Exposure days: 1, 4 and 7, **Exposure day 7 
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2.6  HBO treatment  
 
The Hyperbaric Animal Research Chamber OXYCOM 250 ARC (HYPCOMOY, Tampere, 
Finland) was used (Fig. 8). This pressure chamber is cylindrical with an inner diameter of 25 
cm, and an inner length of 55 cm, and a volume of 27 litres. The chamber is equipped with a 
gas in-and out-let, and a manometer for chamber pressure monitoring. 
 
 
Figure 8: The hyperbaric oxygen chamber. 
 
 
A pure O2 environment can cause fire. The chamber was therefore litter and oil free. The 
chamber was flushed with pure O2 (medical quality). After reaching 100% O2 after 15 min, 
the pressure was raised over a period of approximately 5 min to 2.5 bar (corresponding to 15 
msw). The 2.5 bar pure oxygen atmosphere was maintained for a period of 90 min to 
complete treatment according to protocol. To ensure >97% O2 atmosphere, the chamber was 
flushed with pure oxygen for 3-5 min every 10-30 min depending on the number of mice in 
the chamber. After completion of the 90 min treatment, the chamber was decompressed 
slowly over a period of 10 minutes. 
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2.7 Measurement of tumour growth 
 
The tumours were measured externally with a calliper at day 1 (pre HBO exposure), day 4 
and 8 (post HBO exposure). The location of the tumour excluded external measurements in 
more than two dimensions. Tumour volume was therefore calculated assuming a cylindrical 
form of the tumour according to the equation: 
 
Equation 3: Tumour volume equation. 
 
 
 
Tumour volume = 
6
pi
 · a
2  
· b 
 
where a is the shortest and b is the longest transversal diameter. 
 
On day 1 the tumour position and shape was drawn on a schematic mouse, to ensure that the 
tumour was measured in the same position at day 4 and 8. 
 
2.8 Ex-vivo and in-vivo imaging 
 
When finishing the tumour growth measurements, the mice were sacrificed by injecting 
saturated KCl into the heart under anaesthesia and the tumour excised. The excised tumours 
were then cut in two. One half was fixed in formalin (4%) and later embedded in paraffin for 
immunohistochemical analysis. The other half was frozen in liquid nitrogen and stored at        
-80ºc until further use. A third group of tumours were fixed in paraformaldehyd (PFA), prior 
to freezing, and the frozen sections were later imbedded in Prolong Gold (Invitrogen, 
California, USA). This was done to be able to benefit from the fluorescent traits of the tumour 
when visualized under the microscope (Leica TCS SP5, Wetzlar Germany). 
 
In addition, some of the tumours were used for taking in situ microscopy pictures, by 
anesthetizing the mouse and removing the skin flap, exposing tumour and surrounding tissue 
to appropriate UV-illumination. The tumours were visualized using a Nikon C-DSD230 
(Nikon, Japan). Further, flowcytometri was performed with dissociated tumours resuspended 
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in PBS. The dissociated cells were sorted on a fluorescence-activated cell sorter (FACS Aria 
SORP, BD Biosciences, Erembodegem, Belgium) on the basis of single-cell viability and the 
presence of eGFP and dsRed. 
 
2.9  Immunohistochemistry-staining for CD31 
 
The frozen tumour tissue was embedded in Tissue Tek (Sakura Finetek Europe, 
Zoeterwounde, Holland) and cut into 20 µm slices using a cryostat (Leica CM 3050 S-
Cryostat, Nussloch, Germany). 
 
Rat anti-mouse CD31 (AbD serotec, Morphosys UK Ltd, Oxford, UK) is commonly used 
when staining for blood vessels in mouse tissue [60]. We used the Two-Step indirect staining 
method with a monoclonal antibody. This is a standard protocol utilized in 
Immunohistochemistry [61]. 
 
A monoclonal antibody is an immunohistochemically identical antibody produced by a clone 
of plasma cells, and they react with a specific epitope on a given antigen. The primary 
antibody needs to be specific to the species the tissue is collected from. We chose Rat anti-
Mouse (AbD serotec, Morphosys UK Ltd, Oxford, UK) as we wanted to stain mouse tissue. 
The secondary antibody needs to be specific for the species that produced the primary 
antibody and we used Rabbit Anti-Rat, as the anti-Mouse antibody was produced in a rat 
(Vectastatin nABC kit, peroxidase Rat IgG PK 4004, Bioteam AS, Trondheim, Norway). 
Since the secondary antibody was produced in rabbit, we added a rabbit blocker prior to the 
secondary antibody so that the epitopes were saturated and the antibody could only attach to 
the antigens we were interested in. This blocking step prevented us from getting cross 
reactions. Between each step the slices were washed. 
 
To be able to recognise the secondary antibody, we used an ABC kit (Vectastatin, Peroxidase 
Rat IgG PK 4004, Bioteam AS, Trondheim, Norway). The secondary antibody was pre-
tagged with biotin by the manufacturer, and when adding the Avidin-Biotin complex it bound 
to the biotin tag. To achieve colour we added Diaminobenzidine tetrahydrochloride (3.3 
DAB, Sigma-Aldrich, Germany) which is an electron donor. This step oxidized the complex 
and resulted in a dark brown colour. We achieved a colour reaction after 90 seconds. The 
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reaction was then stopped by rinsing with PBS. Subsequently we stained the tissue section 
with Richardson stain and the tissue turned blue in contrast to the dark brown blood vessels 
(Fig. 9).  
 
 
 
 
Figure 9: An example of CD-31 stained tumour tissue from the control group. Blood vessels are 
stained dark brown, while the tumour tissue is stained blue. 
 
 
All sections were examined using a (THP Eclipse E600, Nikon Corporation, Tokyo, Japan), 
and six to nine images were captured covering the whole tumour area (Nikon Digital Camera 
DXM 1200F, Nikon Corporation, Tokyo, Japan). All blood vessels were counted manually 
and the average number (vessels/mm2) was then calculated for each tumour. This procedure 
was performed blindly. 
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2.10  The wick-in-needle (WIN) technique 
 
The interstitial fluid pressure (Pif) was measured by the wick-in-needle (WIN) technique [62, 
63]. 
 
In the WIN technique a multifilamentous nylon thread was placed within a fine hypodermic 
needle (23g, outer diameter: 0.6mm). Initially, we used a needle with a 2 to 4 mm long side 
hole, but since the tumours were very small in the mice we had difficulty placing the two 
holes in the middle of the tumour, and started using a standard 23g treaded needle. The needle 
was connected to a transducer dome through a PE-50 catheter (Fig. 10). Two, three-way 
stopcocks were placed on each side of the pressure transducer. One of the stopcocks was used 
for the possibility of flushing if bubbles were to appear in the system. The second stop cock 
was used to calibrate the system to air and water column (13.6 cm H2O=10mmHg). The 
system was filled with saline, and we ensured that there were no leakages or air bubbles 
throughout the system, as this could affect the result. The transducer was connected to 
pressure-measurement software (PowerLAb/ssp ADinstruments, PowerLab chart 5, version 
5.11).  
 
 
 
 
Figure 10: The pressure transducer dome (A) connected to the wick-in-needle (B). 
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The system was calibrated as follows: The transducer was levelled with the tumour. The 
normal air pressure was measured by opening the system to air and setting the powerlab-level 
to 0 mmHg. A 27,2 cm water column was connected to the transducer, and the pressure of the 
column was measured and regulated to 20 mmHg on the PowerLab.  
 
The needle was inserted into the middle of the tumour and left in place without fixation (Fig. 
11).  
 
 
 
Figure 11: Wick-in-needle placed in tumour. 
 
 
The fluid communication between the interstitium and the measuring system was ensured by 
compressing and decompressing the catheter (clamping). This caused a transient rise and fall 
in pressure. To get a valid Pif measurement the pressure had to return to pre-clamp value  
(± 1 mmHg).  
 
Due to initial problems with Pif measurements, we modified the protocol slightly when 
measuring Pif. We added heparin (5000IE/a.e./ml, Heparin LEO, LEO Pharma AS, Ballerup, 
Denmark) to the NaCl (8 drops heparin in 50 ml NaCl). This was performed to prevent the 
needle from clogging when being placed in what turned out to be very angiogenic tumours. 
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2.11  Hydroxyproline analysis (collagen content quantification) 
 
To determine the amount of collagen in the tumours, we used the hydroxyproline analysis 
[64]. The tumours were free of fat and freeze-dried before the analysis started.  
 
The tumour tissue was finely crushed and weighed before being hydrolysed. This was 
performed in sealed glass test tubes together with 0.5 ml HCl 37%, premixed in a solution of 
0.5 ml double distilled water (ddH2O), and left overnight at 120°C. The content was allowed 
to reach room temperature before rinsing and diluting with ddH2O to a total volume of 4 ml.  
 
Samples were further diluted with additional ddH2O. The volumes of ddH2O we added, 
depended on the amount of freeze dried tissue in the test tube (mg), and were calculated 
according to the equation: 
 
 
Equation 4: Dilution of samples for hydroxyproline analysis 
 
(225 / X mg freeze dried tissue / 4mL) x 5 
 
 
All test tubes now contained a total volume of 4.5 ml and a final tissue concentration of  
0.25 µg/µL. Five hundred µl of this solution was placed in a soft plastic test tube for later use. 
The standard reagents were made by adding a known amount of hydroxyproline stock 
(Appendix) and each standard solution (containing increasing amount of hydroxyproline) was 
later pipetted (500 µl) into soft plastic tubes.  250 µl Chloramine-T was added to all samples, 
both standards and tumour tissue. Twenty min later, 250 µl Perchloric acid was added and 
mixed uniformly with the solutions. This was left for 5 min before adding the p-DABA (250 
µl). After mixing, the tubes were placed in a water bath keeping 60 ± 1°C, for 20 min. In 
order to stop the reactions, the test tubes were placed in ice cold water for 5 min.   
 
Sample sizes of 250µL were dispensed in duplicates into microplates with 96 wells 
(MaxiSorp, NUNC, Denmark). The absorbance of the samples was read at 557 nm using a 
spectrophotometrical microplate reader (Molecular Devices SpectraMAx Plus 384, GMI Inc., 
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USA). The results were displayed through a computer (Pentium Processor with Windows 
XP), using software Softmax PRO (Molecular Devices, USA).  
 
A standard curve was made that correlated with the amount of hydroxyproline in  
125 µg of the sample tissue. Total collagen concentration was correlated to hydroxyproline by 
a factor of 6.94 (µg collagen / µg hydroxyproline). 
 
2.12  Microdialysis 
 
To determine the uptake of radioactive labelled 5FU ([3H]-5FU) (Nycomed Amersham, 
Buckinghamshire, UK) into the tumour tissue, we used the microdialysis technique [65], 
which is further modified in our laboratory [66].  
 
The mouse was anaesthetized with Hypnorm-Dormicum as previously described (Chapter 
2.3). An intravenous cannula was inserted in the tail vein for administration of the [3H]-5FU. 
Microdialysis probes were inserted in the jugular vein (A) and another in the tumour (B) (Fig. 
12), so we could sample dialysate from both plasma and the central tumour throughout the 
protocol.  
 
 
 
Figure 12: The microdialysis probe placed in the jugular vein (A) and in the tumour (B). A cannula 
was inserted in the tail vein (C) for drug administration. 
 
 
A 
B 
 
C 
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Prior to insertion, the probes were placed in 70% alcohol for 10 min in order to dissolve 
protective fat from the probe membrane. Both probes were connected to a pump (CMA-100, 
Microdialysis AB, Stockholm, Sweden). In the first 5 min the probes were perfused with 30 
µl NaCl, thus removing possible bubbles from the probe-catheters. The perfusion was then 
reduced to 5 µl/min for 5 min, and then further reduced to 1 µl/min for the final 5 min. The 
[3H]-5FU was injected immediately after the completion of the equilibration phase and the 
saline rate was kept at 1 µl/min. 
 
The sampling of dialysate started immediately after the injection of the [3H]-5FU through the 
intravenous catheter, and samples were collected every ten min for a total of 70 min (Fig. 13). 
 
 
Figure 13: Protocol for the microdialysis experiments after repeat hyperbaric oxygenation (HBO) 
treatment. 
 
 
One ml of counting cocktail (High Flash-point LSC cocktail, Ultima Gold, Packard, 
Groningen, Holland) was added to all samples in order to be able to count radioactivity. 
Radioactivity was measured with a ß-counter (QuantaSmart for the TriCarb liquid 
scintillation). The area under the curve (AUC) for both plasma and tumour was calculated as 
the products of counts per 10 min (cpm) for a total measurement period of 70 min. Transport 
of [3H]-5FU was expressed as AUC tumour/AUC plasma.  
 
The group of mice receiving 1 single treatment of HBO was prepared for sampling by 
inserting the probes prior to entering the hyperbaric chamber. This was done due to the fact 
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that the [3H]-5FU had to be administered immediately after completing the HBO treatment 
together with the sampling of plasma, while the pO2 was still high in the tumour tissue (Fig. 
14). 
 
 
 
 
 
Figure 14: Protocol for the microdialysis experiments after single hyperbaric oxygenation (HBO) 
treatment. 
 
2.13  Statistics 
 
 We used the two-tailed unpaired t-test (normalized data) or one-way ANOVA (non-
normalized data) for testing the statistical differences between groups. Differences were 
accepted as statistically significant at p<0.05. Standard deviations or standard errors of mean 
are indicated in Figures and Tables. The software program SPSS for Windows was used for 
statistical analysis. 
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3  Results 
 
3.1  Establishing mammary-tumours 
 
One of our main goals was to establish two new dsRed transfected mammary tumours in 
eGFP expressing mice. This required that different approaches to the testing were applied, 
before ending up with a protocol that was both trustworthy and functional. 
  
A pilot study was initiated by injecting 2x106 cells in two mice for each cell line so as to 
evaluate if this number of cells was sufficient to establish tumours. Both cell lines were 
counted and dissolved in PBS before being injected in the mouse fat pad, as described in 
chapter 2.1 and 2.4.  
 
When injecting 2x106 4T1 cells in the mice had a 100% take rate (number of mice obtaining a 
tumour), within a latency period of 10 days (Table 3). The latency period indicate the number 
of days passed until the tumour was palpable (measuring ~3mm in diameter). A similar 
amount of MCF7 cells in the mice had no take rate (Table 3). 
 
 
Table 3: The effect of injecting two different cell lines on take rate and latency period. 
 
 
 
 
 
                   
                   * followed for 8 weeks 
 
 
 
 
Cell lines Amount of cells 
Injected (0,2 ml) 
Take rate Latency 
period 
MCF7 2 million 0/2 -* 
4T1 2 million 2/2 10 days 
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A tumour stock was obtained by freezing 4T1 tumour tissue for later use, as described in 
chapter 2.4. The tissue (2x2mm) was minced and inserted into the fat-pad of 5 mice. None of 
the mice developed tumours as shown in Table 4. We, therefore, decided to proceed with the 
cell lines as stock, and not the tumour tissue pieces, in order to ensure tumour growth. 
 
 
Table 4: The effect of tumour tissue injected in mice on take rate and latency period. 
 
 
 
 
 
  
                                     *followed for 5 weeks 
 
 
The number of 4T1 cells was increased from 2 x106 to 3x106 cells in the eGFP mice, in an 
attempt to reduce the latency period. This was successful as we had a 100 % take rate within 5 
days after injections (Table 5). Thus, in all our following experiments we injected 3 x106 4T1 
cells, and Table 5 illustrates the reliability of the model.  
 
 
Table 5: The effect of 4T1 cells injected in mice on take rate and latency period. 
 
 
 
 
 
 
 
 
 
 
 
Tumour tissue 
   (2x2 mm) 
Take rate Latency 
period 
4T1 0/5 -* 
Cell line Amount of cells 
injected 
(0.15ml) 
Take rate Latency period 
4T1 3 million 52/52 5 days 
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Due to the lack of take when inserting 2 million MCF7 cells, the amount of cells was 
increased to 5 x106 cells. However, as this did not result in tumour growth (Table 6) the cell 
line was injected in combination with Matrigel. This combination resulted in tumour take in 
∼80% of the mice as illustrated in Table 6. 
 
Table 6: The effect of MCF7 cells injected in mice, with and without Matrigel, on the take rate and 
latency period. 
 
 
* followed for 8 weeks 
 
 
However, as the cells grew both in conjunction with and also underneath the Matrigel “plug”, 
it was difficult to distinguish the tumour cells from the Matrigel by both palpating (not able to 
use calliper in a correct way) and visualization. More studies and time are needed to develop 
this model to its full potential.  
 
Due to time limitations we abandoned the MCF7 tumour model at this stage. Therefore, 
only the 4T1 model is included when elucidating the effect of HBO on mammary tumours. 
 
 
 
 
 
 
 
 
Cell line Matrigel Amount of cells 
injected (0.25 ml) 
Take rate Latency 
period 
Not given 5 million 0/2 -*  
MCF7 
 
0.25 ml 5 million 4/5 10 days 
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3.2  Fluorescent imaging 
 
To verify that the dsRed transfected cells had developed a tumour in the eGFP mice, we used 
a fluorescence dissection microscope with UV-filter optics for dsRed and eGFP. As shown in 
Fig. 15, a detailed red tumour is seen within the surrounding green host tissue. Thus, we had 
successfully established dsRed transfected 4T1 mammary tumours subcutaneously (sc) in the 
eGFP mice. The overall tumour surface architecture was visualized, and blood tumours within 
the tumour bed appeared darker. We could also clearly see the vasculature in the skin flap as 
well as the transition areas between tumour tissue and host tissue. 
 
 
 
 
 
Figure 15: An in situ picture of a 4T1 dsRed tumour growing subcutaneously in the NOD/Scid eGFP 
expressing mouse after removing the skin flap (x4 magnification). 
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To visualize the tumour content (tumour cells vs host cells) we used a confocal microscope 
(Leica TCS SP5, Wetzlar, Germany). Pictures were taken of PFA fixated cryostat slides, 
covered with prolong gold. We showed that the tumours contained both pure red tumours 
cells as well as infiltrating eGFP expressing host cells (Fig. 16).  
 
 
Figure 16: Example of a confocal microscopy picture of 4T1 mammary tumour cells growing in an 
eGFP expressing mouse ( from the control group). Scalebar indicates 250 µm (A) and 50 µm (B). 
  
Dissociation of the 4T1 mammary tumour into a single cell suspension consisting of tumour 
cells (red) and host cells (green) (Fig. 17), was performed with a collagenase cocktail prior to 
flowcytometry. Flowcytometry enables us to separate, sort and quantify the red and green 
cells (performed by Linda Stuhr and Jian Wang). The follow up of this line of investigation is 
beyond the scope of this thesis (see further studies). 
 
 
 
Figure 17: The dissociated 4T1 mammary tumour showing that there are single green host cells 
together with single ds Red transfected tumour cells (x10 magnification). 
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3.3  Effect of hyperoxia on the 4T1 mammary tumours 
 
3.3.1 Tumour growth 
 
A total of 19 controls and 24 repeated HBO treated 4T1 mammary tumours were measured 
with a calliper as described in chapter 2.7. 
 
On day 1 tumour size averaged 80 mm3. The control tumours increased in size with ~800 % 
within the first 8 days of tumour development, showing very aggressive behaviour (Fig. 18). 
Due to the rapid tumour growth rate in the control group, we decided to end the protocol at 
this point, as further tumour growth would not be ethical.  
 
Exposing the mice to 2.5 bar pure oxygen, 3 times each for 90 min, significantly reduced 
tumour growth compared to control during the same time period (Fig. 18). 
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Figure 18: 4T1 mammary tumour growth (% of initial volume) in control (n=19) and repeated 
hyperbaric oxygen (HBO) treated tumours (n=24) during an 8 day period. Treatments were given day 
1, 4 and 7. Mean ± SEM. * p<0.001 compared to control. 
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3.3.2  Tumour blood vessels 
 
Angiogenesis is pivotal for tumour growth, and may be a strong contributor to the differences 
in size found in the 4T1 mammary tumours between controls and the repeated HBO treated. 
We therefore wanted to elucidate the average number of tumour blood vessels (blood 
vessels/mm2) by using rat anti-mouse CD31 as primary antibody, as described in chapter 2.9. 
 
The 4T1 cells had a dense vasculature. However, the blood vessel density in the repeated 
HBO treated tumours was significantly decreased compared to control (Fig.19).  
 
Thus, repeated HBO treatments (only 3 exposures) have an anti-angiogenic effect on the 4T1 
mammary tumours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: The average blood vessel density from 6-9 representative cross section pictures from 5 
controls and 5 repeated hyperbaric oxygen (HBO) treated 4T1 mammary tumours. Mean ±SEM.  
* p<0.001 compared to control. 
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3.3.3  Histology 
 
Two 20 µm paraffin embedded 4T1 mammary tumour sections, from both control and 
repeated HBO exposed tumours, were stained with haematoxylin-eosin (Fig. 20). This was 
performed so as to be able to elucidate any major changes in the histology, as previously 
found in DMBA-induced mammary tumours after HBO repeated treatment. 
 
There were some changes between the control tumours and the repeated HBO treated tumours 
as we found indications of more necrosis in the two control slides compared to the HBO 
treated. However, to be able to draw a conclusion we need to stain more tumours and 
correlate the histological findings with proliferating and apoptotic measurements using 
immunohistochemistry.  
 
 
 
 
Figure 20: Examples of haematoxylin-eosin stained tumour tissue of the peripheral (A and B) and 
central (C and D) parts of the 4T1 mammary tumour in control (left) and repeated hyperbaric oxygen 
(HBO) treated (right). The images are scaled to the same magnification (x4). 
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3.3.4  Interstitial fluid pressure (Pif) in the tumours 
 
Pif was measured in the centre of the 4T1 mammary tumour with the WIN technique, as 
described in chapter 2.10.  
 
The Pif is usually high in solid tumours. This was also true for the 4T1 control tumours 
measuring an average of 7.2 mmHg ± 1.3 mmHg. However, the average Pif in the repeated 
HBO treated group was 3.7 mmHg ± 1.0 mmHg.  
 
Thus, this shows a significant 50% reduction in Pif in the repeated HBO treated tumours 
compared to the control group. A similar reduction was found in the single HBO treatment 
group, 3.8 mmHg ± 0.7. 
 
 
 
Figure 21: Interstitial fluid pressure measurements in control (n=11), repeated hyperbaric oxygen 
(HBO) treated (n=11) and single HBO treated (n=8) 4T1 mammary tumours. Average values are 
indicated as small, horizontal lines. Mean ± SEM * p <0.05 compared to control. 
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3.3.5  Hydroxyproline quantification 
 
To quantify the collagen content in the tumours, we used the hydroxyproline method as 
described in chapter 2.11.  
 
The results show no statistically significant differences in the collagen content between the 
two groups after 8 days. Thus, 3 repeated HBO treatment did not change the density of 
collagen fibrils in the interstitium. 
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Figure 22: The average collagen content after 8 days in control (n=7) and in repeated hyperbaric 
oxygen (HBO) treated 4T1 mammary tumours (n=8). Mean ± SEM. 
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3.3.6  Uptake of [3H]-5FU  
 
The uptake of the radioactive labelled chemotherapeutic drug [3H]-5FU into the tumour tissue 
was measured with microdialysis, as described in chapter 2.12. 
 
We started with 6 mice in each group, but due to difficulties (probably anaesthetics), 2 mice 
in the repeated HBO treated group and 1 in the acute group died during measurements. Due to 
time limits for the thesis work, we did not have time to compensate for this.  
 
The result showed no increase in the uptake of [3H]-5FU into the tumour tissue neither after 
long term nor single HBO treatment group compared to control.  
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Figure 23: Uptake of radioactive labelled 5-fluor uracil ([3H]-5FU) in control (n=6), in repeated 
hyperbaric oxygen (HBO) treated (n=4) and in single HBO treated (n=5) 4T1 mammary tumours. 
Average values are indicated by small, horizontal lines.
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4 Discussion 
 
The strengths and potential weaknesses of the applied methods used in this present study are 
discussed first. Then, a general discussion of the results is presented before being summarized 
into a conclusion.  
 
4.1 Methodological aspects 
 
4.1.1 Cell lines 
 
We wanted to establish two new mammary tumour models to try to verify the tumour 
attenuation found in the DMBA mammary tumours after HBO exposure [47]. The dsRed 4T1 
murine breast carcinoma cell-line and the dsRed MCF7 human adenocarcinoma cell-line were 
used to establish tumours in an eGFP-expressing immunodeficient mouse model. 
 
The 4T1 cell line is one of very few mammary tumour cell lines that have the ability to 
metastasize to sites affected in human breast cancer, when injected into immunodeficient 
mice. This includes metastasis to liver, lungs, bone and brain [54], making it a good model 
mimicking human breast cancer and metastasis [55]. A further step in this direction is the use 
of the MCF7 mammary tumour cell line which has previously been shown to form tumours in 
immunodeficient mice [56]. The combined use of these two models will enable us to better 
understand the human disease and, thereby, improve current treatment options.  
 
4.1.2 Culture conditions 
 
Our choice of media was the complex medium called RPMI 1640, a choice supported in the 
literature when nurturing the 4T1 and MCF7 cell lines [54, 56, 67]. It is originally derived for 
human leukemic cells, but it supports a wide range of mammalian cells making it a suitable 
option for our two adenocarcinoma cell lines [68]. 
 
All cell culture work was performed in a sterile environment taking the necessary precautions 
to avoid contamination of the cell culture. Potential sources of contamination were avoided 
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throughout the project, like other cell lines, laboratory conditions and human errors. Thus, we 
experienced no such major problems in our cell-culture work. Due to increased cell passages 
over time, the cells were regularly screened for expression of dsRed. A strong fluorescent 
dsRed expression was found at all times.  
 
4.1.3 Animals and tumour establishment 
 
Cancer research is highly dependent on reliable animal models, which allow us to study 
different aspects of cancer initiation and progression in vivo [13]. In vitro studies will not 
allow us to elucidate the complex tumour –host interactions. When establishing a xeno-
transplantation tumour model in a living organism, it is desirable that the animal is 
immunodeficient so that it will not reject foreign material. Immunodeficient mice, such as 
nude mice, and NOD/Scid mice, are therefore commonly used as in vivo cancer models [69]. 
In this study we used NOD/Scid eGFP-expressing mice, all bred at University of Bergen. The 
strain is well characterized and breeds well [13].  
 
The immunological profile of the eGFP mice was comparable to the non-transgenic parental 
line, the NOD/Scid mice. Tumour take and progression were also similar between the two 
mice lines [13], making it acceptable to include both strains in our experiments.  
 
One of the advantages of using eGFP as a marker is the quick and simple detection procedure, 
since GFP expression was detectable by observation of the tail or fingers under a fluorescent 
microscope immediately after birth. 
 
The eGFP mice must be used within 3 months after birth, as the fluorescent trait of the eGFP 
declines after this age, and their immune system gradually recovers. Therefore, all the mice 
used in this study were under 3 months of age. 
 
In order to develop tumours, a certain number of cells are needed. However, the number of 
cells required varies substantially in the literature, both between different cell lines as well as 
within a certain cell line [54, 56]. We therefore chose to do a series of pilot studies before 
planning and conducting the present study. In conclusion, injection of 5x106 MCF7 cells in 
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combination with matrigel and 3x106 4T1 cells were adequate for initiating tumour growth, in 
addition to being reproducible. 
 
Oestrogens (oestradiol and oestrone) appear to have a crucial role in the initiation and 
progression of breast cancer [1]. Oestrogen supplements are, therefore, often given to the 
experimental animals in order to establish tumour growth and progression [1, 56].  In the 
present study, 17 β estradiol was therefore administered to the mice, prior to injecting both 
cell lines [59]. 
 
It has been claimed that matrigel is necessary for some cell lines to develop into a solid 
tumour. Matrigel has shown to be effective for the attachment and differentiation of the 
human tumour cells (MCF7) when injected in the mouse tissue [56, 67, 70]. Thus, when 
tumours did not develop after injecting 5x106 MCF7 cells, we injected matrigel in 
combination with the cells. Although tumours developed when using matrigel, the MCF7cells 
grew both in conjunction with and also underneath the matrigel “plug”. This made it difficult 
to distinguish the tumour cells from the matrigel by both palpation (not able to use calliper in 
a correct way) and visualization. A previous study has shown that the histology of the 
tumours induced by injection of cells in the presence of either matrigel or culture medium was 
similar [56]. Despite this knowledge, we need to take into consideration the presence of 
matrigel when dissociating the tumour to perform flowcytometry, as the matrigel might affect 
our results. Reducing the amount of matrigel to a minimum would probably be the best way 
to achieve a successful model. By doing so, it would be easier to palpate, thus measuring 
growth with a calliper. The possibility of generating artefacts (matrigel) in flowcytometry 
would also be minimized. Thus, we need to do further experiments to develop this model to 
its full potential. Due to time limitations for the master thesis we, therefore, abandoned the 
MCF7 tumour model at this stage. The model will be followed up in Further Studies, (see 
chapter 4.4) as a human cell line makes the experiments more clinically relevant.  
 
4.1.4 Anaesthesia 
 
Two different types of anaesthesia were used, Isoflurane combined with N2O (gas 
anaesthesia) and Hypnorm-Dormicum (conventional anaesthesia). Gas anaesthesia is the 
preferred option and is therefore commonly used among veterinarians. Furthermore, gas 
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anaesthesia was chosen because most experimental protocols and procedures were short, and 
was utilized when performing injection of cells, insertion of ß-estradiol pellets as well as 
when measuring tumour size and Pif. We assume that the Isoflurane does not affect the results 
in this study, since it is not distributed systemically. 
 
Hypnorm-Dormicum was used during the microdialysis procedure as this was a procedure 
that extended over a longer time period, and in addition required full immobilization of the 
animal. Physical movement and transportation of the animal under gas anaesthesia was not 
recommended, as the mouth nozzle can easily be disturbed, thus risking recovery of the 
animal during the procedure. Since the animals had to be moved during the microdialysis 
procedure Hypnorm-Dormicum was chosen. The subcutaneous injection of Hypnorm-
Dormicum could, in theory, cause local inflammation at the injection point, due to a high 
concentration of alcohol and alkaline pH. However, this is not likely since the injection point 
was kept in distance of the sampling points.  
 
The mice loose their ability to maintain their body temperature when undergoing anaesthesia. 
Thus, an artificial heating source was utilized during surgical and experimental procedures, 
keeping the rectal body temperature of the mouse at approximately 37°C at all times. 
 
We do not believe that the anaesthesia used in this study affected our results. And if so, all 
groups received the same amount of anaesthesia and would therefore be equally affected.  
 
4.1.5 HBO treatment 
 
A pure oxygen atmosphere in the hyperbaric chamber can cause fire if adequate precautions 
are not taken. The chamber was therefore kept litter- and oil-free. 
 
A previous study showed that, 2 bar pure O2 gave a clear attenuation in DMBA induced-
tumour growth [47]. Further studies showed that the reduction in tumour size was 
significantly higher at 2 bar than after 1 and 1.5 bar hyperoxia treatments [46]. Thus, a 2.5 bar 
ambient pressure was chosen in this study to potentiate a possible effect. 
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Toxic effects of oxygen have been observed in the central nervous system and in the lungs at 
high doses (>2.5 bar) or over prolonged exposures (daily exposures for several weeks). The 
central nervous system and pulmonary toxicity included seizures, visual changes, sweating, 
muscle twitching, coughing, pulmonary fibrosis and shortness of breath [34]. However, 
moderate pressure up to 2.5 bar pure O2 was both safe and clinically relevant (used in 
different treatment regimes UHMS, as shown in the Appendix A) [71, 72]. Thus, the ambient 
pressure, oxygen concentration and number of exposures chosen in this thesis made the risk 
of toxicity remote. We did not observe any symptoms of toxicity during our experiments, 
indicating that the treatment protocol was safe.  
 
We initially set up an experimental protocol of four, each of 90 min HBO exposures, over a 
period of 11 days, as this protocol had previously shown to give maximum effect on DMBA 
induced tumour growth [47]. However, as the 4T1 mammary tumours grew substantially, the 
control mice had to be sacrificed on day 8 and we had to modify the initial protocol to include 
only three, exposures of 90 min, over a 7 day period.  
 
4.1.6 Tumour growth 
 
The tumour growth was measured externally with a calliper. This was performed to follow the 
effect of the HBO treatments and to elucidate if it had an effect on the 4T1 tumour growth 
over time, as shown previously in the DMBA induced tumours in rats [47]. Tumour 
development is commonly measured externally with a calliper [54, 67]. However, some have 
claimed that this method might be subjective and hard to reproduce [73]. To justify the use of 
this method, the same investigator performed all calliper measurements in the present study. 
All post-treatment measurements were performed with the mice in non-numerical order. 
Furthermore, any subjective inaccuracy in the measurements would most likely apply for both 
groups, giving a correct ratio and acceptable results.  
 
An alternative growth measurement procedure is to weigh the tumours at the end of the 
experiment. This would not clarify the difference in growth rate, as the tumour can only be 
dissected out when terminating the experiment. However, as we had difficulties dissecting out 
the whole tumour, due to its aggressive behaviour and invasive character, this was not 
considered to be a satisfactory option. 
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We calculated the tumour size assuming a cylindrical form. The shape of the tumours is not, 
however, the shape of a perfect cylinder, and this would affect the results. Also, the 
measurements were performed externally making it impossible to determine the definite 
shape of the tumour, as some of them would progress and invade internal tissue. However, we 
chose two dimensions on every tumour and the relative tumour growth would therefore be 
comparable between the two groups. 
 
4.1.7 Immunohistochemistry 
 
CD 31 has long been considered a good and reliable marker for blood vessels, and is 
extensively used in the literature [60]. It is an ideal marker for microscopic imaging studies as 
it has several desirable features: It is expressed only on the cell type of interest, it is absent 
from other cells, and it has a good signal-to-noise ratio with surrounding tissue [74]. 
However, only recently has it been realized that lymphatic endothelial cells share many 
markers in common with vascular endothelial cells. CD 31 is an endothelial marker, present 
in both blood vessels and lymphatics, although at a lower level of expression on the lymphatic 
endothelial cells [74]. Thus, since tumours contain very few lymphatics, compared to other 
tissues [22], CD31 is considered the best choice when staining for blood vessels in tumours. 
  
Background staining is one of the most common problems in immunohistochemistry, and it 
can seriously affect the interpretation of the immunologic reaction. A common cause of 
background is the hydrophobic interactions of proteins. When blocking is not performed, the 
primary antibody can bind unrelated antigens in the tissue section, producing background 
staining. Adding a blocking protein prior to incubating with the primary antibody normally 
prevents background staining. It is normally performed with the same species to the 
secondary antibody, but it can also be done by adding bovine serum albumin, fish gelatine, 
foetal calf serum, non-fat dry milk and casein [61]. In the present experiments we blocked 
background staining by adding rabbit serum.  
 
The antigen-antibody reaction cannot be visualized without labelling. Labels need to be 
attached to the final antibody (primary or secondary), providing a detection system that allows 
imaging of the immune-reaction. The detection systems are classified as direct or indirect 
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methods. The direct method is the simplest one to use since it only involves one-step; namely 
detection of primary antibody. The indirect method involves two-steps, adding both primary 
and secondary antibodies, and allows for a more sensitive and specific reaction than the direct 
method. The sensitivity of this method is higher than the direct method because the primary 
antibody is not labelled, resulting in a retained activity and strong signal. Thus, we chose the 
indirect method when staining for CD31. 
  
Further, we used the common avidin-biotin complex (ABC) method. One of the main 
disadvantages of using the avidin-biotin system is the possibility of producing high 
background. Avidin can produce background by binding to lectins in the tissue through its 
carbohydrate groups and also through electrostatic binding [61]. We used DAB to colour the 
antigen-antibody reaction. It is the most commonly used chromogen, giving a brown colour, 
and it is insoluble in organic solvents. The choice of counterstain will mainly depend on the 
colour of the immune reaction. The counterstain needs to produce enough colour so as to 
avoid confusion with the DAB precipitate. We therefore used the Richardson stain as it stains 
the tissue lightly, without interfering with the precipitate of the DAB.  
 
It is important to verify the result of the staining by always including a negative control slide. 
To the negative control slide only secondary antibody is added. The control slide should, 
therefore, come out unstained since the secondary antibody is only supposed to bind to the 
lacking primary antibody.  
 
After staining with CD 31, the tumour sections were visualized and prepared for 
quantification. All stained vessels were encircled by hand, and this could be a potential source 
of subjective error in our experiments. All vessels, that were counted, exhibited certain 
predetermined traits (e.g. a clear lumen). Thus, we believe that by being consistent in 
counting all vessels in the same matter, the risk of human error could be minimized. Further, 
the quantification was performed blindly, by interchanging between the control and HBO 
treated group, reducing the risk of being subjective. 
 
The sections used for fluorescent imaging were fixed in PFA prior to freezing. Since GFP is 
very soluble in water, special considerations were taken when handling frozen sections. Even 
after fixation with acetone, the rinsing with water made the GFP dissolve very rapidly and 
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diffuse. For this reason the tumours were fixed with PFA before being frozen, maintaining the 
fluorescent properties of the eGFP machine [58]. 
 
4.1.8 The wick-in-needle technique 
 
Pif was measured by the WIN technique. The pressure was measured in a saline line brought 
into contact with the interstitium through a needle with a nylon wick inside. The WIN 
technique was developed by Fadnes and coworkers [62], in an attempt to combine desirable 
features from two older pressure-measurement techniques; the needle method and the wick 
method. The goal for developing this technique was to increase the contact area with the 
interstitium, while maintaining the simple introduction into the tumour made possible by the 
needle method [63]. 
 
There were several criteria that had to be fulfilled in order to accept the measurements. The 
pressure in the system rose after insertion of the needle into the tumour, until it equilibrated 
with the tumour pressure. It was, therefore, important that the fluid in the interstitium and the 
saline in the measuring device had sufficient time to equilibrate. The time required for the Pif 
pressure recordings to stabilize with needle-based measurements is approximately 1 min, but 
can be as short as 10 s or as long as 5 min [4]. In our procedures equilibration time was 
between 1-5 min.  
 
Pif can be measured in tumours as small as 7-8 mm in diameter, which applies to the size of 
the 4T1 tumours on day 8. However, when the tumour is small you have to take extra 
precautions. You have to ensure that the needle side-hole is placed near the centre of the 
tumour where the Pif is relatively uniform and not near the periphery where there is a region 
of a low Pif gradient [4]. As we had difficulties ensuring that the side-hole was placed in the 
middle of the tumour, we decided to make needles without the side-hole. This ensured that we 
measured Pif in the centre of the tumour. This alteration did not induce any problems for Pif 
measurements, as it only reduced the surface contact area. 
 
Inserting a needle into a tumour may damage blood vessels. This was easily recognized by a 
continuous rise in the interstitial pressure, and such results were discarded. The 4T1 tumours 
proved to be very angiogenic and we had to discard tumours due to clogging (continuous rise 
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in measurements). We therefore decided to further alter the protocol by adding Heparin to the 
NaCl in the system (8drops/50ml), in order to maintain fluid communication between the 
interstitial fluid and the saline in the WIN-system. The alternative was to remove the needle 
from the tumour and flush it, and subsequently replace it in the tumour. However, multiple 
measurements over minutes or hours in the same tumour may falsely lower the Pif readings, 
because of vascular and interstitial damage as well as fluid leakage from the needle puncture 
site [4]. Thus, instead of flushing the needle we added the heparin to prevent clotting at the 
needle point.   
 
The fluid communication in the WIN has to be ascertained with clamping and the 
measurement has to return to pre-clamp values (± 1mmHg). All accepted measurements 
exhibited satisfactory fluid communication between the needle and the surrounding 
interstitium by being stable and returning to pre-clamp values. Therefore, we assume that the 
measured pressures represent true Pif values.  
 
Micropuncture is another well established technique for measuring Pif and much used in our 
laboratory. The reason for not using micropuncture in this study is as follows: Although this 
technique is less traumatic and has a smaller probe and volume than the WIN, it only allows 
pressure-measurements up to a few millimetres into the tissue. The micropipette has therefore 
commonly been used to measure Pif in skin. To be able to use this technique in tumours we 
would have had to remove the skin flap and expose the tumour. Exposure of the tumour in 
this way could induce inflammation, and would most likely affect the pressure measurements. 
Furthermore, when accessing the tumour directly, the micropipette would only reach the 
peripheral part of the tumour, whereas we are interested in measuring Pif at its highest in the 
central part. Additionally, micropuncture measurements require a total immobilization of the 
tissue, which is not possible due to the mouse respiratory movements. 
 
4.1.9  Collagen content-Hydroxyproline analysis 
 
Total collagen content was analyzed according to the method described by Woessner [64]. 
Hydroxyproline is widely used as to determine collagen content. The analysis is associated 
with several pitfalls as it is a procedure highly dependent on precision and accuracy with 
regards to volumes, reaction times and temperatures, making it vulnerable to human errors.  
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The hydroxyproline assay includes two different protocols depending on the amount of 
hydroxyproline expected to be found in the respective tissue (Method 1: for samples 
containing >2% hydroxyproline; Method 2: for samples containing <2% hydroxyproline). We 
used method 2 for the tumour tissue, as this had previously been performed on tumours in our 
lab, and shown to be satisfactory.   
 
In our experiments, only 1/3 of the tumour was set aside to perform this analysis, in order to 
maxify the use of the tumour tissue and thereby reducing the number of mice used. However, 
it would be of interest to measure the collagen content in relation to the weight of the whole 
tumour, as the collagen content is not homogenous throughout the tumour. This might be 
examined in a future study.  
 
4.1.10 Microdialysis 
 
The microdialysis technique was applied to determine the uptake of [3H]5FU into the tumour 
tissue. Microdialysis is the only technique that allows continuous sampling of small 
molecules over an extended period of time. This provided us with the opportunity to study the 
whole time course for the event of capillary-to-tissue exchange. Microdialysis has the 
advantage of being relatively a traumatic, an important trait, since inflammation in the tissue 
could increase the extravasations of molecules from the blood vessels, and thereby affect the 
result [66]. 
 
The principle for microdialysis is based on the fact that molecules diffuse across a semi-
permeable membrane as a consequence of a concentration gradient. In our mouse model this 
phenomena will appear between the serum (jugular vein) or extracellular fluid (tumour) and 
the saline in the microdialysis probe. The [3H]5FU will diffuse towards the fluid with the 
lowest concentration, ie. into the microdialysis probe, as described by Ficks’s law. 
 
The pore size of the microdialysis probe can influence the result, as the pores determine the 
size of the molecules that can equilibrate between the saline and the interstitial fluid. A cut off 
of 100.000 Daltons, allows the [3H]5FU (~70 000 Daltons) to equilibrate and freely diffuse 
across the probe membrane, making it possible to sample through the probes [66]. We have 
modified the protocol slightly by shortening the equilibration phase from 45 to 15 min in 
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order to successfully complete measurements without risking the probability of the mouse 
dying due to the combination of surgery and a long anaesthetic period. The fact that the 
sampling site for microdialysis lies so close to the capillary wall, markedly reduces the time 
required to obtain a steady state, and allows the use of this technique also with shorter 
equilibration time.  
 
The perfusion rate will also influence the result, as higher perfusion rates will tend to dilute 
the samples. The probes were perfused with 1µl/min, for a period of 70 min which gives the 
fluids sufficient time to equilibrate, in addition to obtaining more concentrated samples [66].  
 
All the ß-countings were performed in the same counter to minimize any possible error in 
counting.  
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4.2 Results 
 
4.2.1 Tumour growth and angiogenesis 
 
 
Hypoxia is a common feature in tumours, and it is generally accepted that it promotes 
aggressive tumour behaviour, invasiveness and metastatic potential [35, 48, 75] in addition to 
angiogenesis. With this in mind, we wanted to investigate the effect of hyperoxic treatments 
(“the flip of the coin”) on tumour growth and angiogenesis in the 4T1 mammary tumours.  
 
The present study showed a significant reduction in tumour growth after three, 2.5 bar, 
repeated HBO treatments over a period of 8 days, compared to control. This is in agreement 
with the reduction found in DMBA-induced mammary tumours after both 1 bar and 1.5 bar 
HBO treatments [46]. However, in the DMBA-induced mammary tumours undergoing 2 bar 
HBO treatments [47, 48] the tumour size on day 11 was smaller than at day 1. This indicates 
that the DMBA induced mammary tumours respond to hyperoxia in a dose-dependent matter. 
For this reason we chose to treat the 4T1 mammary tumours with 2.5 bar, expecting a 
potentiated effect. However, the 4T1 mammary tumours did not respond to the same extent as 
the DMBA tumours.  
 
The difference in tumour growth response to the HBO treatment was, however, not 
unexpected since cancer is a group of diseases with large variation, and the effect of the 
treatment depends on several factors, including tumour -type and -stage. Thus, this might 
explain the discrepancy in the magnitude of response between the two different mammary 
tumour models.  
 
Another explanation might be that there is a difference in oxygen response between the 
different tumour types. Previous in vitro studies show that some cell lines are oxygen resistant 
[51]. This is reflected in the literature where patients with head and neck cancers tend to be 
most responsive to HBO therapy, and patients with cervical cancer least responsive [42]. As 
we wanted to elucidate if HBO treatments had an inhibiting effect on mammary tumour 
growth in general, we can conclude that HBO inhibits mammary tumour growth, although to 
a varying degree, in the two models studied until now. It will also be of interest to complete 
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the MCF7 human mammary tumour model, to see whether these tumours are affected by 
HBO treatment. This would bring us closer to determine if HBO has a general and similar 
effect on mammary tumours.  
  
As mentioned earlier, angiogenesis is essential for tumour growth and has been shown to be 
hypoxia-induced. We found a significant reduction of angiogenesis in the repeated HBO 
treated 4T1 mammary tumours compared to control, when staining for CD31. Two studies on 
DMBA induced mammary tumours correspond to these findings by showing a marked 
reduction in density of tumour blood vessels after HBO treatments [46, 48]. Moen et al. [48] 
confirm these findings with gene expression analysis, showing a down-regulation of pro-
angiogenic genes. Further, a similar anti-angiogenic effect was found in transplanted gliomas 
in rats after 2 bar repeated HBO treatment [49]. This anti-angiogenic effect most likely 
explains, at least to some extent, the growth inhibition of the HBO treated tumours in the 
present study.  
 
The reason for the anti-angiogenic effect of hyperoxia might be, at least in part, the 
transcription factor hypoxia-inducible factor-1 (HIF-1). HIF-1 mediates tumour survival and 
growth in the hypoxic environment, and consists of α- and β-subunits. HIF-1α is activated by 
decreased oxygen tension and responds by inducing expression of a set of genes involved in 
angiogenesis [76, 77]. Vascular endothelial growth factor (VEGF) is activated by HIF-1α in 
response to hypoxia, and regulates endothelial cell proliferation and blood vessel formation. 
Since HIF-1 and VEGF are known to be oxygen dependent [35], it is reasonable to assume 
that the elevated pO2 induced by HBO treatment will reduce HIF and VEGF levels. Gene 
expression analysis, performed by Moen et al. on 2 bar hyperoxic treated DMBA induced 
mammary tumours, confirms this hypothesis by showing a significant down-regulation of 
VEGF [48]. To confirm this in our 4T1 mammary tumours, gene expression profiling will be 
performed (see Further Studies).  
 
Lately, a normalization hypothesis has been put forward stating that anti-angiogenesis therapy 
may transiently normalize tumour vasculature [10, 29]. Several authors have shown that the 
normalized vasculature after anti-angiogenic therapy had less leaky tortuous vessels, with 
more normal basement membranes and better pericyte coverage, and that these structural 
changes were accompanied by normalization of the tumour microenvironment [78, 79]. Lee et 
al. [80] supports this by stating that it is the quality of the vascular organization and not just 
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the quantity of the vessels that determines the vessel function. Since HBO treatment initiate 
anti-angiogenesis in the present study, one might speculate that the blood vessels have 
become normalized and thus are functionally changed. We, therefore, believe that the 4T1 
mammary tumours respond to hyperoxic treatments by inducing a decreased amount of blood 
vessels as well as normalizing the remaining vessels.  
 
Other factors than angiogenesis are also likely to be involved in 4T1 mammary tumour 
growth inhibition. Apoptosis is one of these. A significant increase in cell death was 
previously found after repeated hyperoxic treatment in DMBA induced mammary tumours 
[48]. They show that several factors in the apoptotic machinery were influenced by HBO. 
Among these were an increased number of TUNEL positive tumour cells in the HBO treated 
group. This corresponds with previous findings in DMBA induced mammary tumours after 1 
and 1.5 bar hyperoxic treatment [46], as well as in transplanted gliomas in nude rats after both 
1 and 2 bar treatment [49].  
 
Another important factor likely to contribute to tumour growth inhibition is reduced tumour 
cell proliferation. Decreasing tumour cell proliferation is a direct inhibition of dividing cells, 
hence preventing tumour growth. Recent studies with HBO treatment have shown to 
significantly decrease tumour cell proliferation in the DMBA-induced mammary tumours 
(personal communication with Moen et al). Granowitz et al. [43] support this by showing that 
HBO treatments inhibit both benign and malignant human mammary epithelial cell 
proliferation in vitro.  
 
We therefore want to utilize the 4T1 mammary tumour tissue that we already have collected, 
to study both proliferation and apoptosis by using the marker Ki67 and TUNEL staining (see 
further studies). This enables us to further explore the mechanisms behind the tumour growth 
inhibition induced by HBO treatments in the 4T1 mammary tumours. 
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4.2.2 Uptake of chemotherapy and the microenvironment 
 
4.2.2.1 Uptake of [3H]-5FU 
 
One of the major challenges in cancer therapy is the resistance to chemotherapy. As 
mentioned previously, delivery of systemically administered chemotherapeutic agents to the 
tumour tissue depends on the fact that the drug must reach the target cells, and in addition be 
effective in the tumour microenvironment. There are four main factors to take into 
consideration when exploring the obstacles of chemotherapeutic effect: 
 
1. Hypoxia 
2. Interstitial hypertension (↑ Pif) 
3. Dense ECM (↑ collagen fibrils) 
4. Angiogenesis 
 
Hypoxia 
Chemotherapy target rapidly proliferating cells. Hypoxic tumour cells are non-proliferating, 
and therefore less susceptible to chemotherapy. Previous studies have shown that HBO 
treatments potentiate the effect of chemotherapeutic agents like doxorubicin, alkylating agents 
and 5-FU [34, 81, 82]. Stuhr et al. [47] showed a significant growth reduction in DMBA-
induced mammary tumours when administering 5-FU immediately before hyperoxic 
treatments. Furthermore, personal communication with Moen et al. shows an increase in the 
uptake of [3H]-5FU in DMBA induced mammary tumours, when administered immediately 
after a single treatment of 2 bar hyperoxia of 90 min, compared to control and repeated HBO 
treatments. This indicates that the drug uptake is stimulated by pO2, thus HBO was expected 
to potentiate chemotherapy, also in the present study. Surprisingly, we did not find increased 
uptake of [3H]-5FU in neither the single nor repeated HBO treated 4T1 mammary tumours 
when compared to control. The reason for this is not yet elucidated.  
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Interstitial hypertension 
Since Pif was decreased in both repeated as well as single HBO treated 4T1 mammary 
tumours, there is reason to believe that the reduction in Pif is caused both by an increase in 
pO2 (single treatments) as well as by long term vascular changes in the tumour (repeated 
treatments). Solid tumours commonly exhibit interstitial hypertension. Several investigators 
have shown increased uptake of chemotherapeutic agents after a decrease in tumour Pif [4, 5, 
28, 83]. Due to the decrease in Pif, an increase in the uptake of [3H]-5FU would also be 
expected in the present study. Surprisingly, this was not the case in the present study. 
 
As mentioned earlier, small molecules are primarily distributed through diffusion and are 
much less affected by an enhanced Pif. However, macromolecules, such as monoclonal 
antibodies and large molecule chemotherapeutic agents, accumulate through convectional 
trans-capillary transport, which is counteracted by the increased Pif [12]. 5-FU being one of 
the smaller chemotherapeutic agents, might move by diffusion, and therefore remain less 
affected by the decrease in Pif. However, previous studies have shown an enhanced uptake of 
[3H]-5FU in combination with HBO treatment, indicating that [3H]-5FU moves by convection 
[47, 81] Still, we plan to perform microdialysis with a large molecule chemotherapeutic agent 
in the future to elucidate any differences compared to the uptake of [3H]-5FU (Further 
Studies).  
 
The normalization of the tumour vasculature might have an effect on tumour Pif, by reducing 
the leakiness of the vessels
. 
This has been shown in both preclinical and clinical trials. This 
implicates that normalization of the tumour vasculature is probably, at least partly, 
responsible for the reduction in tumour Pif induced by repeated HBO exposure. However, 
anti-angiogenic therapy can decrease the overall distribution of large molecules in the 
interstitium [84, 85], and decrease blood perfusion [86]. Since hyperoxic treatment has an 
anti-angiogenic effect on the 4T1 mammary tumours, this will together with a possible 
reduced permeability, impede trans-endothelial transport of [3H]-5FU even though Pif is 
lowered. This could explain why the uptake of [3H]-5FU was not increased in the 4T1 
mammary tumours.  
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Dense ECM 
After a drug molecule has been filtered out of the blood vessels and into the interstitium, the 
drug transport and penetration are dependent on the composition and conductivity of the 
interstitium [87]. Netti et al. [32] showed that tumours with a more extended collagen 
network was more penetration-resistant. Furthermore, a study degrading collagen enhanced 
the interstitial diffusion rate and intra-tumoural delivery of drugs [88]. Our 4T1 mammary 
tumours showed no statistical significant difference in the amount of collagen content 
between the groups, possibly explaining why there was no difference in the uptake of [3H]-
5FU. Thus, the finding of the present study corresponds with the findings of previous studies 
[32, 88], that a rich collagen network counteracts drug uptake.  
 
However, previous studies on DMBA induced mammary tumours show that repeated HBO 
exposures decrease the collagen content in the tumours [48]. These findings are paradoxical 
since HBO treatment of normal tissue induces the formation of collagen (e.g. wound healing) 
[34]. Although the HBO treated 4T1 mammary tumours did not show a statistically 
significant decrease in collagen content, they showed a tendency toward a reduction in the 
HBO treated group compared to controls. As mentioned earlier, we had to modify our 
treatment protocol to include 3 instead of 4 hyperoxic treatments. Thus, one might speculate if 
there were too few treatments in the study, and hence too little time to induce a change in 
collagen content. Further studies involving a total of at least 4 treatments in the HBO treated 
group will be performed to conclude whether a similar response is obtained in the 4T1 
mammary tumours (see Further Studies). Therefore, increasing the number of treatments is an 
attempt to clarify if HBO, over an extended time period, could reduce the collagen content in 
the 4T1 mammary tumours, and thereby increase the uptake of [3H]-5FU.  
 
Furthermore, Eikenes et al. show that a reduction in collagen content is associated with a 
reduced tumour Pif [88] and thus, supports the view that changes in the structural network of 
the tumour interstitium affects the tumour Pif [12, 89]. Our findings in the 4T1 tumours do not 
support this, as the differences of collagen content in the two groups were not statistically 
significant despite significant differences in Pif. 
 
 
 
 
                                                                                                                                    Discussion 
 63  
Angiogenesis 
Tumour anti-angiogenic therapy was a promising prospect when first introduced by Folkman 
et al. [90] in the early 70es. Their view was that tumour survival depended upon a functional 
vascular system and by inhibiting the tumour vasculature, the tumour cells would die. 
However, a major concern regarding anti-angiogenic therapy was its contraindications when 
combined with the more traditional treatment forms of chemotherapy and radiotherapy. Since 
chemotherapy is distributed systemically it needs a functional vascular system to be able to 
reach the targeted tumour cells. Radiotherapy, although not distributed systemically, also need 
a vascularised and oxygenated tumour to be successful. Thus, clinical trials combining anti-
angiogenic therapy together with chemotherapeutic agents and radiotherapy were conducted. 
Surprisingly, the trials showed improved anti-tumour outcomes when using anti-angiogenic 
therapy in combination with chemotherapy and radiotherapy [78, 91]. The suggestion is that 
the tumour microenvironment becomes normalized, leaving the tumour cells to be more 
effectively inhibited by chemotherapeutics or rendered more sensitive to radiotherapy [10]. 
The findings of our study do not support this view. Despite a significant decrease in 
angiogenesis and thus assuming normalized blood vessels, we did not measure increased 
uptake of [3H]-5FU in the HBO treated group. Thus, it is probable that the normalization of 
the vasculature, resulting in less leaky vessels, counteracts the delivery of [3H]-5FU to the 
4T1 mammary tumours. 
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4.3 Conclusion 
 
We had 3 main aims in this study, and these have been addressed: 
 
1. Establish two new mammary tumour models by using eGFP expressing 
immunodeficient mice and dsRed transfected tumour cells 
• We established a reliable and reproducible 4T1 mammary tumour model successfully. 
This model is invaluable in our long term scope of studying tumour host interactions. 
• We also established a MCF7 mammary tumour model, but this model needs to be 
further refined to reach its full potential. Due to time limitations the MCF7 model was 
abandoned at this stage. 
 
2. Elucidate the possible effect of hyperbaric oxygen treatment on tumour growth 
and angiogenesis. 
• Repeated HBO treatments significantly inhibited growth and angiogenesis in the 4T1 
mammary tumours. The HBO induced anti-angiogenesis can, to some extent, explain 
the tumour growth inhibition, since angiogenesis is pivotal for tumour growth.  
 
3. Analyse the effect of HBO on the tumour interstitium (Pif and collagen content) 
as well as the effect of drug uptake (chemotherapeutic effect).  
• The Pif in the 4T1 mammary tumours was significantly reduced after both single and 
repeated HBO treatment, compared to control. Thus, the reduced Pif is probably a 
response to both an increase in pO2 as well as long term vascular changes in the 
tumour tissue. 
• Surprisingly, repeated HBO treatment did not reduce the collagen content in the 4T1 
mammary tumour model. However, it is possible that the relative short treatment 
period (8 days) was not sufficient to induce such a change.  
• Despite the decrease in tumour Pif we found no increase in the uptake of [3H]-5FU in 
neither the repeated nor the single HBO treated group when compared to control. This 
was unexpected and contradictory to findings in the DMBA induced tumours where 
the [3H]-5FU increased after a single HBO treatment.  
 
 
                                                                                                                                    Discussion 
 65  
4.4 Further Studies 
 
The present study is the initial part of a larger study, focusing on the tumour micro-
environment. The eGFP mice with the dsRed transfected mammary tumours present us with a 
model that allows us to completely separate the pure tumour cells (red) from the stromal cells 
(green). This provides us with the opportunity to analyse differences in each of the cellular 
compartments, before and after treatment, on both gene and protein level. The normal 
surrounding cells are of special interest, as we believe that they contribute to the aggressive 
behaviour of tumours. Our ultimate goal is to be able to elucidate and target leading molecular 
pathways. Further, we can study tumour-host cell interactions both in situ and ex vivo on a 
detailed cellular level. 
 
The fluorescent model further provides us with the opportunity to detect circulating metastatic 
cells [13], as it has been reported that 4T1 tumour metastasizes to liver and lungs as early as 8 
days post tumour transplant [54]. This is a trait that would be of interest for us to study in a 
future HBO experiment, questioning if HBO can hinder metastasis. 
 
The present study showed that our MCF7 mammary tumour model needs to be refined. One 
approach is to reduce the Matrigel volume needed to a minimum, thus making the tumours 
easier to palpate and measure. The risk of contamination during flowcytometry is also 
probably reduced when using smaller amounts of Matrigel, and might even be abolished if the 
volume is so small that the Matrigel have time to disintegrate within the experimental period.  
 
In the future, we would like to increase the number of treatments over an extended time 
period, and elucidate how this affects the tumours. In addition we want to study post-
treatment effects.  
 
We will also combine HBO therapy with other chemotherapeutic agent than the 5-FU, to 
analyze any differences in the uptake and effect between the drugs. 
 
Last but not least we will further, elucidate the influence of apoptosis (TUNEL staining) and 
proliferation (with Ki67) on tumour growth. 
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6 Appendix 
 
Appendix A 
 
UHMS approved indications for Hyperbaric Oxygen Therapy 
 
• Air or gas embolism 
• Carbon monoxide poisoning, cyanide poisoning, smoke inhalation 
• Clostridial myostitis and myonecrosis (gas gangrene) 
• Crush injuries, compartment syndromes and acute traumatic peripheral ischemias 
• Decompression sickness 
• Enhancement of healing in selected problem wounds 
• Exceptional blood loss anaemia 
• Intracranial abscess 
• Necrotizing soft tissue infections 
• Refractory osteomyelitis 
• Skin flaps and grafts (compromised) 
• Delayed radiation injury (soft tissue and bony necrosis) 
• Thermal burns 
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Appendix B 
 
Cell freezing protocol: 
 
1) Grow cells in a 600ml (big) culture-flask to ~70% confluence. 
 
2) Withdraw and discard the medium. 
 
3) Expose the cells briefly to Trypsin. Use ~3ml 4°C Trypsin/ 25 cm2, make sure to 
cover the cells completely! Leave for a few seconds and then withdraw the Trypsin. 
Make sure the monolayer has not yet detached! 
 
4) Trypsinize the cells for 5 -10 min, until the cells detach and round up. Loosen the 
cells from the bottom by gently knocking the bottle against the table or the palm of 
your hand. NOTE: Be careful not to leave the cells in Trypsin longer than necessary, 
and do not force the cells to detach before they are ready to do so. Carefully watch 
the ongoing process by using a compound microscope.  
 
5) Add 5ml. medium to inhibit the trypsin activity. Disperse cells by pipetting over the 
bottom surface, and then pipette the suspension gently up and down sufficiently to 
disperse the cells into a uniform single cell suspension.  
 
6) Spin down the suspension in a table top centrifuge. 900 RPM, 5 min. Discard the 
supernatant.  
 
7) Resuspend the pellet in 2ml. Freezing-medium, containing: 
                                                       1700 µl Medium 
                                                       100 µl FCS 
                                                        50 µl DMSO 
 
8) Dispense cell suspension into two 2ml prelabeled plastic ampules and seal carefully. 
NOTE: The ampules should carry a label with the cell strain designation, passage 
number, the date of freezing and the user’s initials.  
 
9) Place the ampules on a proper rack and chill at -20°C o/n. 
 
10) Transfer the cells to a -70°C freezer o/n.  
 
11) Finally transfer the cells to permanent storage in a liquid nitrogen freezer.  
  
12) When ampules are safely located in the (l) N2-tank, make sure that the appropriate 
entries are made in the Freezer-Index. Records should contain the exact position on 
the different boxes in the tank, as well as the contents in each box; cell line and 
passage number, and the date of freezing.  
 
Last, but not least; Make sure there is enough Nitrogen in the tank at all times!! 
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Appendix C 
 
The cells were trypsinized and added more medium than cellsuspension. 
Pipette up in centrifuge-tubes. 
Centrifuger at 900 rpm for 4 min. 
Make solution 1 and 2. 
 
Solution 1: 
 
9 ml DMEM Alt (with 10% calf serum) 
+1 ml calf serum. 
= 10 ml DMEM Alt med 20% FCS 
 
Solution 2: 
DMSO (Dimethylsulfoksyd, 200 mg/ml (20%), 10 ml (from Haukeland Hospital pharmacy). 
Draw 10 ml DMSO up into the centrifuge-tube with solution 1. 
 
This corresponds to a 10% DMSO with 10% calf serum in DMEM Alt-medium. This is the 
freeze medium. 
 
After thawing the medium from the centrifuged cells add 1-2 ml freeze medium to each cryo-
tube.  
 
Place the samples in an Isopropanol container keeping room temperature.  
Place the container in an -80 oC freezer for 16-24 hours. 
Transfer the samples than to liquid nitrogen.  
 
